Ethyl 5-cyano-4-(3,5-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Ethyl 5-cyano-4-(3,5-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate
• 化学式: C₁₇H₁₆Cl₂N₂O₂
• 分子量: 351.2
• InChiKey: BHEWLUJMDJVBBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  62.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Method of treating proliferative diseases using Eg5 inhibitors
  申请人：——

  公开号：US20020165240A1

  公开（公告）日：2002-11-07

  The invention provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor. The invention also provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor in combination with at least one other anti-cancer agent.

  本发明提供了一种通过调节Eg5蛋白活性治疗疾病的方法，包括向需要此类治疗的哺乳动物物种中给予至少一种小分子Eg5蛋白抑制剂的有效量。本发明还提供了一种通过调节Eg5蛋白活性治疗疾病的方法，包括向需要此类治疗的哺乳动物物种中给予至少一种小分子Eg5蛋白抑制剂和至少一种其他抗癌剂的有效量。
• EP1372657A4
  申请人：——

  公开号：EP1372657A4

  公开（公告）日：2005-11-09
• A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1372657A2

  公开（公告）日：2004-01-02
• [EN] A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS<br/>[FR] TRAITEMENT DE MALADIES PROLIFERATIVES AU MOYEN D'INHIBITEURS DE EG5
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2002078639A2

  公开（公告）日：2002-10-10

  The invention provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor. The invention also provides a method for treating a condition via modulation of the Eg5 protein activity comprising administering to a mammalian species in need of such treatment an effective amount of at least one small molecule Eg5 protein inhibitor in combination with at least one other anti-cancer agent.